Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1
- PMID: 11311097
- DOI: 10.1001/jama.285.16.2083
Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1
Abstract
Context: Zidovudine reduces maternal-infant transmission of human immunodeficiency virus 1 (HIV-1) infection by two thirds. Combination antiretroviral therapies are potentially more effective prevention.
Objectives: To assess the safety of perinatal lamivudine-zidovudine therapy, especially in children, and its effects on viral load, acquisition of drug resistance, and maternal-infant transmission of HIV-1 in a nonbreastfeeding population.
Design and setting: The Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study, an open-label, nonrandomized intervention trial conducted in the context of an ongoing observational cohort study in 48 sites in France.
Patients: A total of 445 HIV-1-infected pregnant women were enrolled as the study cohort from February 1997 to September 1998; controls consisted of 899 pregnant women who had received zidovudine monotherapy in May 1994 to February 1997 as standard care.
Intervention: The study cohort received lamivudine in addition to the standard Pediatric AIDS Clinical Trial Group 076 Study zidovudine prophylaxis regimen. Lamivudine was initiated in women at 32 weeks' gestation through delivery at 150 mg twice per day orally; children received lamivudine, 2 mg/kg twice per day for 6 weeks.
Main outcome measures: HIV-1 infection status and tolerance of therapy in children through age 18 months; maternal plasma HIV-1 RNA levels through 6 weeks after delivery.
Results: The transmission rate in the study group was 1.6% (7/437; 95% confidence interval [CI], 0.7%-3.3%). In a multivariable analysis, transmission in the study group was 5-fold lower than in controls. In the study group, maternal plasma HIV-1 RNA level was less than 500 copies/mL at delivery in 74%; the median decrease was 1.24 (range, -1.63 to 3.40) log(10) copies/mL. The M184V lamivudine resistance mutation was detected at 6 weeks after delivery in specimens from 52 of 132 women. The most frequent serious adverse events in children were neutropenia and anemia, requiring blood transfusion in 9 children and premature treatment discontinuation in 19. Two uninfected children died at age 1 year from neurologic complications related to mitochondrial dysfunction.
Conclusions: Lamivudine-zidovudine may be effective in preventing maternal-infant HIV transmission. However, severe adverse effects and emergence of resistance to lamivudine occurred. Thus, the role of this combination therapy in this setting is as yet unclear, and further research involving a variety of strategies is needed to definitively ascertain its utility for preventing maternal-infant HIV transmission.
Comment in
-
Combination prophylaxis for prevention of maternal-infant HIV transmission: beyond 076.JAMA. 2001 Apr 25;285(16):2129-31. doi: 10.1001/jama.285.16.2129. JAMA. 2001. PMID: 11311104 No abstract available.
Similar articles
-
Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.Lancet Infect Dis. 2011 Mar;11(3):171-80. doi: 10.1016/S1473-3099(10)70288-7. Epub 2011 Jan 13. Lancet Infect Dis. 2011. PMID: 21237718 Clinical Trial.
-
Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load.JAMA. 1996 Feb 28;275(8):599-605. JAMA. 1996. PMID: 8594240
-
Elective cesarean delivery plus short-course lamivudine and zidovudine for the prevention of mother-to-child transmission of human immunodeficiency virus type 1.Am J Obstet Gynecol. 2004 Mar;190(3):803-8. doi: 10.1016/j.ajog.2003.09.034. Am J Obstet Gynecol. 2004. PMID: 15042018 Clinical Trial.
-
Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.Paediatr Drugs. 2002;4(8):515-53. doi: 10.2165/00128072-200204080-00004. Paediatr Drugs. 2002. PMID: 12126455 Review.
-
Antiretroviral therapy during pregnancy and early neonatal life: consequences for HIV-exposed, uninfected children.Braz J Infect Dis. 2004 Apr;8(2):140-50. doi: 10.1590/s1413-86702004000200004. Epub 2004 Sep 8. Braz J Infect Dis. 2004. PMID: 15361992 Review.
Cited by
-
Profiling Ribonucleotide and Deoxyribonucleotide Pools Perturbed by Remdesivir in Human Bronchial Epithelial Cells.Front Pharmacol. 2021 May 4;12:647280. doi: 10.3389/fphar.2021.647280. eCollection 2021. Front Pharmacol. 2021. PMID: 33995062 Free PMC article.
-
Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.Br J Clin Pharmacol. 2007 Nov;64(5):634-44. doi: 10.1111/j.1365-2125.2007.02885.x. Epub 2007 Sep 24. Br J Clin Pharmacol. 2007. PMID: 17892516 Free PMC article.
-
Regular review: HIV infection in children.BMJ. 2001 Sep 22;323(7314):670-4. doi: 10.1136/bmj.323.7314.670. BMJ. 2001. PMID: 11566832 Free PMC article. Review. No abstract available.
-
Impaired T helper cell responses in human immunodeficiency virus-exposed uninfected newborns.Immun Inflamm Dis. 2021 Dec;9(4):1541-1553. doi: 10.1002/iid3.507. Epub 2021 Aug 19. Immun Inflamm Dis. 2021. PMID: 34409752 Free PMC article.
-
Nano Co-Crystal Embedded Stimuli-Responsive Hydrogels: A Potential Approach to Treat HIV/AIDS.Pharmaceutics. 2021 Jan 20;13(2):127. doi: 10.3390/pharmaceutics13020127. Pharmaceutics. 2021. PMID: 33498151 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical